Backed by International Authority — Caliway's latest preclinical data on its proprietary localized ...
CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide ...
* Clinical results from Caliway's CBL-0204 Phase 2b study of its fat reduction drug candidate CBL...
* Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-...
* Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. F...
* CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the...
* Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025...
* Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the worl...
- Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the wo...
* CBL-514, Caliway's novel small molecule drug, was selected for data presentation at the World O...
Advancing Scientific Recognition in Non-Surgical Fat Reduction * Caliway's CBL-514 Phase 2 study ...
* CBL-514, the world's first investigational drug for large-area localized fat reduction, has dem...
* The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at I...
NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is p...
- CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease tr...
* The first and only lipolytic injectable for large area – CBL-514's last Phase2b study has been ...
NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that ...
NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to an...
* CBL-514 is the first product to treat cellulite at the raised areas. * Currently, there is no ...
* CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track desig...